Amlodipine and Levothyroxine Interaction: What Patients and Clinicians Need to Know

Amlodipine (brand name Norvasc, a dihydropyridine calcium channel blocker used for hypertension and angina) and levothyroxine (brand names Synthroid, Levoxyl, Tirosint, and others, a synthetic form of the thyroid hormone thyroxine) are commonly prescribed together because hypertension and hypothyroidism frequently coexist, especially in older adults. This article is a general educational reference. It is pending qualified clinical review and does not replace individualized advice from the prescriber managing a specific patient's regimen.

The direct answer

There is no known enzyme-level or transporter-level interaction between amlodipine and levothyroxine. Amlodipine is metabolized hepatically, largely through CYP3A4, according to its FDA-approved prescribing information; levothyroxine is not a CYP3A4 substrate, inhibitor, or inducer, so the two drugs do not compete for the same clearance pathway. The clinically relevant issues are separate: (1) levothyroxine is absorbed best on an empty stomach and its FDA label instructs taking it 30 to 60 minutes before food or other oral medications, so co-administration timing with amlodipine can matter for thyroid control, and (2) uncontrolled hypothyroidism or hyperthyroidism changes blood pressure and heart rate in ways that can make amlodipine appear less effective. Neither of these is a contraindication to using both drugs.

Is there a pharmacokinetic interaction?

No meaningful pharmacokinetic interaction has been described between amlodipine and levothyroxine. Amlodipine's FDA label identifies hepatic CYP3A4 as its primary metabolic route and describes interactions with strong CYP3A4 inhibitors (such as clarithromycin, itraconazole, or ritonavir) and inducers (such as rifampin), which can raise or lower amlodipine exposure substantially (per amlodipine's FDA-approved prescribing information). Levothyroxine does not act on CYP3A4 in a way that would place it in that category. This is a well-established pharmacology point, not a novel finding specific to this pairing.

Levothyroxine absorption occurs mainly in the small intestine and is sensitive to gastric pH, food, and certain co-administered substances (calcium salts, iron, antacids, some fiber). Amlodipine is not among the classic offenders documented for levothyroxine malabsorption in the way that calcium carbonate, iron supplements, or proton pump inhibitors are. Whether trace calcium-containing excipients in a given amlodipine formulation meaningfully reduce levothyroxine absorption has not been specifically studied in a way this article can point to; that possibility is plausible by extension from the calcium-levothyroxine literature but not established for amlodipine itself. Because separating the two drugs by 30 to 60 minutes costs nothing and follows the levothyroxine label's own general dosing instruction, it is a reasonable precaution regardless of whether amlodipine specifically interferes.

Where the real risk lives: pharmacodynamics, not pharmacokinetics

Thyroid hormone status changes the cardiovascular system that amlodipine is treating.

Under-replacement (hypothyroidism). Reduced thyroid hormone is associated with increased systemic vascular resistance and can raise diastolic blood pressure and LDL cholesterol. If poor levothyroxine absorption, inconsistent timing, or an insufficient dose keeps a patient under-replaced, blood pressure may run higher than expected on a given amlodipine dose, which can lead a clinician to escalate the antihypertensive when the actual fix is correcting thyroid control.

Over-replacement (iatrogenic hyperthyroidism). Excess levothyroxine can produce tachycardia, reduced vascular resistance, and increased risk of atrial fibrillation, particularly when TSH is suppressed. Amlodipine has only a mild effect on heart rate and is not a substitute for a beta-blocker in this situation. In a patient with angina, hyperthyroid-driven tachycardia and increased myocardial oxygen demand could theoretically worsen anginal symptoms even on a stable amlodipine regimen, though this article cannot point to a verified case series specific to amlodipine to quantify that risk.

Both directions argue for the same practical conclusion: TSH stability matters for how well amlodipine appears to work, independent of any drug-drug interaction.

Evidence-boundary statement

Established: Amlodipine is metabolized by CYP3A4; levothyroxine does not meaningfully affect CYP3A4 activity. Levothyroxine absorption is timing- and substance-sensitive, and its FDA label instructs taking it on an empty stomach, 30 to 60 minutes before food or other oral medication. Uncontrolled hypothyroidism and hyperthyroidism produce well-recognized cardiovascular effects (respectively, increased vascular resistance and tachycardia).

Plausible but not specifically demonstrated: That amlodipine's excipients meaningfully chelate or bind levothyroxine in the gut in a clinically significant way; that combining the two drugs produces a measurable, dose-quantifiable change in TSH beyond what timing and thyroid status alone would predict.

Not established: That amlodipine causes hypothyroidism or otherwise alters thyroid hormone synthesis, binding, or clearance. No mechanism supports this, and this article did not locate evidence of it in the literature reviewed.

Requires verification before clinical reliance: Any specific numeric claim about how much a given co-administration reduces levothyroxine AUC, or any precise TSH target quoted as an official guideline threshold, should be checked against the current American Thyroid Association guideline and the product labeling in effect at the time of use, since levothyroxine dosing conventions and reference ranges are periodically revised.

Evidence-status interaction assessment

Practical timing

A commonly used approach, consistent with the levothyroxine label's own instructions: take levothyroxine first thing in the morning with water, then wait at least 30 to 60 minutes before eating or taking other medications, including amlodipine. Amlodipine has a long elimination half-life (the FDA label describes it in the range of roughly one to two days), so it does not need to be taken at a specific time relative to food; moving it to evening, or to any time consistently 30 to 60 minutes after levothyroxine, is a reasonable way to remove any timing overlap without compromising blood pressure control. Individual dosing decisions should be made with the prescribing clinician.

Monitoring after starting or changing either drug

• TSH and free T4: check at baseline and again after any levothyroxine dose or timing change, per the treating clinician's schedule; thyroid hormone levels take several weeks to re-equilibrate after a change, so early re-checks can be misleading.
• Blood pressure: seated, consistent arm, tracked over time; current hypertension guidelines generally target a systolic/diastolic goal below 130/80 mmHg for most adults, though individual targets vary by age and comorbidity and should be set by the treating clinician.
• Resting heart rate: a persistently elevated heart rate in a patient on levothyroxine warrants a TSH check before assuming it is an amlodipine issue.
• Ankle or leg swelling: amlodipine is a recognized cause of dose-dependent peripheral edema. Hypothyroid-related fluid retention (myxedema) can look similar. New or worsening swelling in a patient on both drugs is worth a TSH check rather than an automatic amlodipine dose change.

Seek urgent care for chest pain, fainting, a very rapid or irregular heartbeat, or signs of a hypertensive emergency (severe headache with very high blood pressure, vision changes, confusion). These symptoms need same-day medical evaluation regardless of what medications a patient is taking.

Other amlodipine interactions worth knowing about

Amlodipine's more consequential interactions involve CYP3A4, not thyroid hormone:

• Strong CYP3A4 inhibitors (clarithromycin, itraconazole, ritonavir, and similar agents) can raise amlodipine blood levels and increase the risk of hypotension or peripheral edema, per the FDA label.
• CYP3A4 inducers (rifampin, certain anticonvulsants) can lower amlodipine levels and reduce its antihypertensive effect.
• Simvastatin: the FDA issued a drug safety communication limiting simvastatin to 20 mg per day in patients taking amlodipine, due to increased myopathy risk from higher simvastatin exposure (per an FDA drug safety communication). This is one of amlodipine's few FDA-labeled dose-limiting interactions and is unrelated to levothyroxine.
• Cyclosporine: the amlodipine label describes increased cyclosporine trough concentrations with co-administration, relevant mainly in transplant medicine.

Levothyroxine does not fall into this higher-risk category with amlodipine.

Substances that affect levothyroxine absorption regardless of amlodipine

Because levothyroxine has a narrow margin between under- and over-replacement, it is worth knowing what else commonly interferes with its absorption, independent of amlodipine:

• Calcium carbonate and other calcium supplements
• Iron supplements (ferrous sulfate and similar)
• Antacids containing aluminum or magnesium
• Proton pump inhibitors, which raise gastric pH
• High-fiber foods and soy products, if taken close to the levothyroxine dose

These are documented in levothyroxine's own labeling and general endocrine practice. Patients taking any of these alongside amlodipine and levothyroxine should mention it to their prescriber, since the absorption issue is with these agents, not with amlodipine itself.

Special situations

Older adults. The amlodipine label recommends a lower starting dose (2.5 mg/day) in this group due to slower clearance. Older adults are also more likely to have reduced gastric acid and to be on a proton pump inhibitor, both of which can reduce levothyroxine absorption, making thyroid monitoring more important in this population.

Pregnancy. Levothyroxine requirements typically increase during pregnancy, and thyroid monitoring is done more frequently in pregnant patients on replacement therapy; this should be managed directly with an obstetric or endocrine provider. Amlodipine's use in pregnancy is an individualized decision made with an obstetric provider, and other agents are often preferred for gestational hypertension. This article does not provide pregnancy-specific dosing guidance.

GLP-1 receptor agonist use. Drugs like semaglutide slow gastric emptying and could plausibly change the timing or extent of levothyroxine absorption, though this article did not find a well-characterized, verifiable study quantifying that effect for this specific combination. Patients starting a GLP-1 receptor agonist while on levothyroxine and amlodipine should mention it to their prescriber so TSH can be rechecked after the change if clinically indicated.

What to bring up with a prescriber or pharmacist

• The exact time levothyroxine is taken relative to amlodipine, food, and any other medications or supplements (this single detail resolves much unexplained TSH variability).
• Any new heart palpitations, unusual fatigue, unexplained weight change, or new swelling.
• Any new OTC supplement, antacid, or PPI use.
• Whether amlodipine dose escalation is being considered for blood pressure that is not at goal, since checking TSH first can sometimes avoid an unnecessary dose increase.